Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Burles A. Johnson"'
Autor:
Sharada Mokkapati, Vikram M. Narayan, Ganiraju C. Manyam, Amy H. Lim, Jonathan J. Duplisea, Andrea Kokorovic, Tanner S. Miest, Anirban P. Mitra, Devin Plote, Selvalakshmi Selvaraj Anand, Michael J. Metcalfe, Kenneth Dunner, Jr., Burles A. Johnson, Bogdan A. Czerniak, Tiina Nieminen, Tommi Heikura, Seppo Yla-Herttuala, Nigel R. Parker, Kimberley S. Schluns, David J. McConkey, Colin P. Dinney
Publikováno v:
Molecular Therapy: Oncolytics, Vol 26, Iss , Pp 141-157 (2022)
Interferon alpha (IFNα) gene therapy is emerging as a new treatment option for patients with non-muscle invasive bladder cancer (NMIBC). Adenoviral vectors expressing IFNα have shown clinical efficacy treating bacillus Calmette-Guerin (BCG)-unrespo
Externí odkaz:
https://doaj.org/article/5de742af926648bcab7840c44c6fac3e
Autor:
Evangelia Vlachou, Burles Avner Johnson, David McConkey, Yuezhou Jing, Andres Matoso, Noah M. Hahn, Jean Hoffman-Censits
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionEnfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4. No validated biomarker predictive of
Externí odkaz:
https://doaj.org/article/1f0b6a04324d4a688f636d0b106bf1d8
Autor:
Evangelia Vlachou, Andres Matoso, David McConkey, Yuezhou Jing, Burles Avner Johnson, 3rd, Noah M. Hahn, Jean Hoffman-Censits
Publikováno v:
European Urology Open Science, Vol 49, Iss , Pp 100-103 (2023)
Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response. In this retrospective single-center study, data
Externí odkaz:
https://doaj.org/article/b433314c102d453b9d1b9b99d3eb8105
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Noah M. Hahn, Michael A. O'Donnell, Jason A. Efstathiou, Marianna Zahurak, Gary L. Rosner, Jeff Smith, Max R. Kates, Trinity J. Bivalacqua, Phuoc T. Tran, Daniel Y. Song, Alex S. Baras, Andres Matoso, Woonyoung Choi, Kellie N. Smith, Drew M. Pardoll, Luigi Marchionni, Bridget McGuire, Mary Grace Phelan, Burles A. Johnson, Tanya O'Neal, David J. McConkey, Tracy L. Rose, Marc Bjurlin, Emerson A. Lim, Charles G. Drake, James M. McKiernan, Israel Deutsch, Christopher B. Anderson, Donald L. Lamm, Daniel M. Geynisman, Elizabeth R. Plimack, Mark A. Hallman, Eric M. Horwitz, Essel Al-Saleem, David Y.T. Chen, Richard E. Greenberg, Alexander Kutikov, Gordon Guo, Timothy A. Masterson, Nabil Adra, Hristos Z. Kaimakliotis
Publikováno v:
European Urology. 83:486-494
Autor:
Kara Lombardo, Andres Matoso, Burles A. Johnson, Noah M. Hahn, Wm. Kevin Kelly, David J. McConkey, Babar Bashir, Jean H. Hoffman-Censits
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 39:619-622
Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortum
Autor:
Burles Avner Johnson, Mingxiao Feng, Woonyoung Choi, Gabriela Colocho, Alyssa Arbuiso, Samuel Jin, Adam K. Aragaki, Charles Ruland, Stanley Rapiey, Noah M. Hahn, David J. McConkey
Publikováno v:
Cancer Research. 83:612-612
Introduction: Developing optimized bladder cancer mouse models that can be used in the evaluation of immune based therapeutics remains a high priority in ongoing research.Experimental Procedures: In previous work by our collaborators, murine cell lin
Autor:
Evangelia Vlachou, Noah M. Hahn, Alix Dabb, Burles Avner Johnson, M. Susan Lefande, Jean H. Hoffman-Censits
Publikováno v:
Journal of Clinical Oncology. 41:523-523
523 Background: In the TROPHY study, 8.8% of the 113 patients (pts) were enrolled post EV treatment, with ORR to SG of 30% in that small subset. Response to SG post EV in real world populations has not been previously reported. SG has accelerated FDA
Autor:
Jean H. Hoffman-Censits, Burles Avner Johnson, Noah M. Hahn, Woonyoung Choi, Armine Smith, Nirmish Singla, David James McConkey, Max R. Kates
Publikováno v:
Journal of Clinical Oncology. 41:TPS599-TPS599
TPS599 Background: Small cell bladder cancer (SCBC) is a rare aggressive bladder cancer (BC) variant comprising
Autor:
Li Luo, Linda M.S. Resar, Donna M. Williams, Burles A. Johnson, Lionel Chia, Noah M. Hahn, Mingxiao Feng, Dominic Dordai, Stephen Desiderio, Jack Mountain, Theodore S. Johnson, Adam K. Aragaki, Ophelia Rogers, David J. McConkey, Wenhao Zhang, Lingling Xian
B cells have been implicated as central regulators of immune responses in settings as diverse as mammalian pregnancy, mucosal tolerance, chronic infection states, autoimmunity, and the tumor microenvironment. Despite the established importance of B c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fca7c880f385244fdb15433e93daf19e
https://doi.org/10.1101/2021.08.25.456776
https://doi.org/10.1101/2021.08.25.456776